A Form 4 filed on August 14, 2026 reports that Mohamed Elshenawy, Chief Technology Officer of Hims & Hers Health, Inc. (NASDAQ:HIMS), was granted 1,200,000 Restricted Stock Units on August 12, 2026.

Key Highlights

  • Grant size: Mohamed Elshenawy received 1,200,000 Restricted Stock Units on August 12, 2026.
  • Security type: Each RSU represents a contingent right to receive one share of Class A Common Stock.
  • Price of derivative security: $0, as reported in Table II of the filing.
  • Vesting schedule: RSUs vest over a 3-year period in substantially equal quarterly installments, beginning with the first Company quarterly vesting date following the grant date.
  • Resulting ownership: Elshenawy beneficially owns 1,200,000 derivative securities following the reported transaction, held directly.
  • Filer role: Elshenawy is identified as Chief Technology Officer of Hims & Hers Health, Inc.

RSU Award Details for Hims & Hers Health CTO Mohamed Elshenawy

According to the Form 4 filed with the SEC on August 14, 2026, Mohamed Elshenawy, the Chief Technology Officer of Hims & Hers Health, Inc. (NASDAQ:HIMS), acquired 1,200,000 Restricted Stock Units on August 12, 2026. The filing records the transaction under Table II, covering derivative securities, with a transaction code of "A" indicating an acquisition. The price of the derivative security is listed as $0.

The filing discloses that the RSUs "represent a contingent right to receive one share of Class A Common Stock for each RSU." The underlying security is Class A Common Stock, with the number of shares underlying the award equal to 1,200,000. Elshenawy holds these RSUs directly, and following the reported transaction his total beneficial ownership of the derivative security stands at 1,200,000 units.

The filing further discloses that the RSUs "shall be subject to a service-based vesting requirement, which shall be satisfied over a 3-year period, with the RSUs vesting in substantially equal quarterly installments on the applicable Company quarterly vesting dates, with the first of such vesting dates to be the first Company quarterly vesting date to occur following the grant date of the award." The form was signed by Kimberly Mather as Attorney-in-Fact for Mohamed Elshenawy and filed on August 14, 2026.

What Was Disclosed

The filing reports a single RSU grant of 1,200,000 units to the CTO of Hims & Hers Health, Inc. on August 12, 2026, with a 3-year quarterly vesting schedule and no exercise price, resulting in direct beneficial ownership of 1,200,000 derivative securities.